Coloplast publishes Q4 2026 earnings call transcript
Coloplast set fiscal 2026/27 targets of 5%-7% organic revenue growth and an EBIT margin around 25%, and revised its ambitions through fiscal 2029/30 to 5%-7% annual organic growth and a mid-20s EBIT margin at constant currencies.
1. Revised ambitions and guidance
At its Nov. 3, 2026, fourth-quarter earnings call, Coloplast said it now aims for annual organic growth of 5%-7% and an EBIT margin in the mid-20s at constant currencies through fiscal 2029/30. For fiscal 2026/27, it targets organic revenue growth of 5%-7% and an EBIT margin around 25%, with improvement expected from the second quarter.
2. Investment and cost program
Coloplast said healthcare pricing pressure, US outpatient Biologics reimbursement changes and increased investment in innovation and US growth contributed to the revised ambitions. Its resource-reallocation program targets DKK 500 million, with approximately 80% earmarked for increased investment and full benefits expected in fiscal 2027/28.
